Pfizer, Takeda settle Protonix patent case with generic drugmakers for $2.15 billion
NEW YORK, N.Y. – Pfizer says it has reached a $2.15 billion settlement with a couple of generic drugmakers over sales of their versions of the heartburn drug Protonix.
The world’s second-largest drugmaker says Teva Pharmaceutical Industries will pay $1.6 billion to Pfizer and Japanese drugmaker Takeda Pharmaceutical.
Another generic drugmaker, Sun Pharmaceutical Industries, will pay $550 million.
Teva is one of the world’s largest generic drugmakers. It started selling its generic version of Protonix in December 2007. Sun launched its own version in early 2008. The drug’s U.S. patent expired in 2011.
Drugmaker Nycomed developed Protonix before the company was purchased by Takeda. Nycomed licensed Protonix to Wyeth, which Pfizer has since purchased.
Pfizer says it will receive 64 per cent of the settlement proceeds.
News from © The Associated Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.
Join the Conversation!
Want to share your thoughts, add context, or connect with others in your community? Create a free account to comment on stories, ask questions, and join meaningful discussions on our new site.
Leave a Reply
You must be logged in to post a comment.